Lymphoma Treatment While Pregnant: Missy's Story

Celebrating her first wedding anniversary and expecting her first child, 25-year-old Missy Givens had a lot to be thankful for. A diagnosis of non-Hodgkin lymphoma turned the mood of celebration into one of concern. The chemotherapy necessary to save Missy's life would put her unborn son at risk for serious birth defects. Despite the odds, Landon was born healthy. Missy finished her lymphoma treatment and was optimistic about the future.

She and her husband did not expect to be able to have more children, but they were blessed with a second pregnancy. A month after Kinley was born, Missy found out her cancer had returned. This time, it was in her bone marrow and stage IV. Here is Missy's story of her struggles with lymphoma while pregnant.

More Videos

Recovery

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap